11 October 2022: Original Paper
Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies
Shu Fang 12ABCDEF* , Nan Wang 23ABCF* , Lili Wang 2ABCD* , Jishan Du 23BCF , Jingjing Yang 23BCF , Yanan Wen 23BCF , Yan Wei 23BCF , Kun Qian 12BCD , Hao Wang 23ABF , Yifan Jiao 23BCF , Chunji Gao 12ACEG* , Liping Dou 2ABDEG*DOI: 10.12659/AOT.937356
Ann Transplant 2022; 27:e937356
Table 3 Univariate analysis of risk factors for grades 2–4 aGVHD and cGVHD in all patients.
| Grades 2–4 aGVHD | Chronic GVHD | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | |
| ATG vs non-ATG | 1.573 | 0.748–3.307 | 0.232 | 0.222 | 0.093–0.530 | 0.001 |
| Recipient age (≥ median vs < median) | 0.962 | 0.457–2.021 | 0.918 | 0.930 | 0.427–2.027 | 0.856 |
| Donor age (≥ median vs < median) | 1.140 | 0.542–2.396 | 0.730 | 1.040 | 0.531–2.039 | 0.908 |
| Donor-recipient gender match | ||||||
| Female to male vs others | 1.091 | 0.493–2.412 | 0.830 | 0.719 | 0.335–1.542 | 0.397 |
| Donor-recipient ABO match | ||||||
| Mismatch vs match | 1.858 | 0.885–3.902 | 0.101 | 1.153 | 0.576–2.308 | 0.688 |
| Diagnosis (ALL vs others) | 1.243 | 0.562–2.748 | 0.591 | 0.396 | 0.153–1.023 | 0.056 |
| Time interval between diagnosis and HSCT | ||||||
| ≥6 m vs | 1.806 | 0.845–3.859 | 0.127 | 0.679 | 0.344–1.339 | 0.264 |
| Cytogenetic risk | ||||||
| High vs favorable/intermediate | 1.854 | 0.868–3.964 | 0.111 | 0.325 | 0.126–0.843 | 0.021 |
| Disease status at HSCT | ||||||
| Untreated/refractory/relapsed vs CR | 0.595 | 0.206–1.715 | 0.336 | 1.531 | 0.692–3.386 | 0.293 |
| Disease risk index | ||||||
| High/very high vs low/intermediate | 1.556 | 0.728–3.322 | 0.254 | 0.313 | 0.121–0.810 | 0.017 |
| MNC (≥ median vs < median) | 1.315 | 0.622–2.781 | 0.473 | 0.535 | 0.268–1.068 | 0.076 |
| CD34 (≥ median vs < median) | 2.026 | 0.935–4.391 | 0.073 | 0.474 | 0.234–0.958 | 0.038 |
| aGVHD (Grades 2–4 vs grades 0–1) | 0.828 | 0.403–1.704 | 0.608 | |||
| ATG – anti-thymocyte globulin; aGVHD – acute graft-versus-host disease; GVHD – graft-versus-host disease; HSCT – hematopoietic stem cell transplantation; ALL – acute lymphoblastic leukemia; CR – complete remission; MNCs – mononuclear cells. | ||||||